In the clinic, breast cancers are classified into HER2amp, hormone receptor positive (HR+), or TNBC subtypes based on the expression levels of the ErbB2 tyrosine kinase and the estrogen and progesterone nuclear hormone receptors (ER/PR). This evidence concerns the gene ERBB2 and breast carcinoma.